The WACC of ANG Lifesciences India Ltd (540694.BO) is 12.7%.
Range | Selected | |
Cost of equity | 20.20% - 23.90% | 22.05% |
Tax rate | 26.30% - 28.80% | 27.55% |
Cost of debt | 7.00% - 15.60% | 11.30% |
WACC | 10.1% - 15.3% | 12.7% |
Category | Low | High |
Long-term bond rate | 6.9% | 7.4% |
Equity market risk premium | 8.3% | 9.3% |
Adjusted beta | 1.6 | 1.73 |
Additional risk adjustments | 0.0% | 0.5% |
Cost of equity | 20.20% | 23.90% |
Tax rate | 26.30% | 28.80% |
Debt/Equity ratio | 2.07 | 2.07 |
Cost of debt | 7.00% | 15.60% |
After-tax WACC | 10.1% | 15.3% |
Selected WACC | 12.7% | |
The Cost of Equity reflects the return a company needs to deliver to shareholders to justify the risk of investing in its shares. It’s computed using the Capital Asset Pricing Model (CAPM), which blends the risk-free rate, the stock’s beta, and the market risk premium.
This method evaluates the stock’s risk compared to a safe investment and the market’s overall volatility.
Here’s how we figure out the cost of equity for 540694.BO:
cost_of_equity (22.05%) = risk_free_rate (7.15%) + equity_risk_premium (8.80%) * adjusted_beta (1.6) + risk_adjustments (0.25%)
We include the risk adjustments, which range from 0% to 1%, to keep our WACC conservatives, especially for companies traded in developing markets.